Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Hayashi, Akimasa ^a,b   Yamauchi, Naoko ^a   Shibahara, Junji ^a   Kimura, Hiroshi ^c   Morikawa, Teppei ^a   Ishikawa, Shumpei ^d   Nagae, Genta ^b   Nishi, Akihiro ^f   Sakamoto, Yoshihiro ^e   Kokudo, Norihiro ^e   Aburatani, Hiroyuki ^b   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ANTIBODY; HISTONE H3; LYSINE; MONOCLONAL ANTIBODY; PROTEIN P53; TUMOR MARKER; BETA CATENIN; HISTONE;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPUTER PROGRAM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; EUCHROMATIN; FEMALE; GENE EXPRESSION REGULATION; HETEROCHROMATIN; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE TRIMETHYLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; TUMOR DIFFERENTIATION; ACETYLATION; CARCINOMA, HEPATOCELLULAR; FLUORESCENT ANTIBODY TECHNIQUE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LIVER RESECTION; METABOLISM; METHYLATION; MULTIVARIATE ANALYSIS; PATHOLOGY; TREATMENT OUTCOME; TUMOR INVASION;

ACETYLATION; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; FLUORESCENT ANTIBODY TECHNIQUE; HEPATECTOMY; HISTONES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYSINE; METHYLATION; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897553622     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091330     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Research FfPoC (2011) Cancer Statistics in Japan 2011.
3. xTakayasu K, Arii S, Ikai I, Omata M, Okita K, et al. (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469. (Pubitemid 44142456)
4. European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943.
5. Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153: 17-37.
6. Shen H, Laird PW (2013) Interplay between the cancer genome and epigenome. Cell 153: 38-55.
7. Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13: 343-357.
8. Selvi BR, Mohankrishna DV, Ostwal YB, Kundu TK (2010) Small molecule modulators of histone acetylation and methylation: a disease perspective. Biochim Biophys Acta 1799: 810-828.
9. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, et al. (2009) Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174: 1619-1628.
10. Chervona Y, Costa M (2012) Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res 2: 589-597.
11. Cai MY, Hou JH, Rao HL, Luo RZ, Li M, et al. (2011) High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 17: 12-20.
12. He C, Xu J, Zhang J, Xie D, Ye H, et al. (2012) High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol 43: 1425-1435.
13. Bai X, Wu L, Liang T, Liu Z, Li J, et al. (2008) Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 83-91. (Pubitemid 350060688)
14. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, et al. (2009) Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459: 108-112.
15. Ong CT, Corces VG (2011) Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet 12: 283-293.
16. Braun M, Kirsten R, Rupp NJ, Moch H, Fend F, et al. (2013) Quantification of protein expression in cells and cellular subcompartments on immunohistochem-ical sections using a computer supported image analysis system. Histol Histopathol 28: 605-610.
17. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694-698.
18. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, et al. (1993) Surgery for small liver cancers. Semin Surg Oncol 9: 298-304. (Pubitemid 23216368)
19. Japan LCSGo (2003) General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 2nd English edition. Tokyo: Kanehara.
20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847. (Pubitemid 28331029)
21. Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N, Nozaki N (2008) The organization of histone H3 modifications as revealed by a panel of specific monoclonal antibodies. Cell Struct Funct 33: 61-73. (Pubitemid 351860902)
22. Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, et al. (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 14: 7237-7245.
23. Song L, Robson T, Doig T, Brenn T, Mathers M, et al. (2013) DNA repair and replication proteins as prognostic markers in melanoma. Histopathology 62: 343-350.
24. Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, et al. (2013) Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. Eur J Surg Oncol 39: 655-661.
25. Torbenson M, Kannangai R, Abraham S, Sahin F, Choti M, et al. (2004) Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma. Am J Clin Pathol 122: 377-382. (Pubitemid 39145542)
26. Salichs E, Ledda A, Mularoni L, Alba MM, de la Luna S (2009) Genome-wide analysis of histidine repeats reveals their role in the localization of human proteins to the nuclear speckles compartment. PLoS Genet 5: e1000397.
27. Bland JM, Altman DG (1995) Multiple significance tests: the Bonferroni method. BMJ 310: 170.
28. Blanche P, Dartigues JF, Jacqmin-Gadda H (2013) Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32: 5381-5397.
29. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344. (Pubitemid 30422619)
30. Ho WH, Lee KT, Chen HY, Ho TW, Chiu HC (2012) Disease-free survival after hepatic resection in hepatocellular carcinoma patients: a prediction approach using artificial neural network. PLoS One 7: e29179.
31. Tandon P, Garcia-Tsao G (2009) Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 29: 502-510.
32. Littau VC, Allfrey VG, Frenster JH, Mirsky AE (1964) Active and Inactive Regions of Nuclear Chromatin as Revealed by Electron Microscope Autoradiography. Proc Natl Acad Sci USA 52: 93-100.
33. Chen X, Cheung ST, So S, Fan ST, Barry C, et al. (2002) Gene expression patterns in human liver cancers. Mol Biol Cell 13: 1929-1939. (Pubitemid 34651483)
34. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392.
35. Yokomizo C, Yamaguchi K, Itoh Y, Nishimura T, Umemura A, et al. (2011) High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett 310: 140-147.
36. Li M, Luo RZ, Chen JW, Cao Y, Lu JB, et al. (2011) High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 9: 5.
37. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92: 1754-1758. (Pubitemid 40756488)
38. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, et al. (2008) The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882.
39. Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, et al. (2011) Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 459: 129-139.
40. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, et al. (2007) Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72: 69-74. (Pubitemid 350249132)
41. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY (1993) Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 53: 4691-4694.
42. Vleugel MM, Shvarts D, van der Wall E, van Diest PJ (2006) p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum Pathol 37: 1085-1092. (Pubitemid 44080822)
43. Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, et al. (2011) Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol 38: 345-353.
44. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, et al. (2004) Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23: 5759-5769. (Pubitemid 39093021)
45. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, et al. (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202. (Pubitemid 44311070)